TVAX Biomedical, a Lenexa, Kansas-based clinical stage development company advancing a proprietary cell-based immunotherapy for the treatment of cancer, has raised $2.0min the first closing of a private round of financing.
TVAX will use these proceeds to continue the clinical advancement of its foundational TVAX Immunotherapy platform, a personalized combination of cancer cell vaccination and “killer” T cell treatment.
In conjunction with the financing, TVAX has appointed Philip Haworth, Ph.D., J.D., as its new chief executive officer, succeeding Gary Wood, Ph.D., who has transitioned to the role of chief science officer.
Participants in the financing included both new and existing private investors. The company plans to raise a total of $10m as part of the round and plans to close the financing’s second tranche in the coming months.